Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

benzinga.com/general/biotech/25/05/45371916/exclusive-alzamend-neuro-initiates-first-phase-2-trial-of-lead-program-in-healthy-human-participa

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects.
This study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical…

This story appeared on benzinga.com, 2025-05-13 11:30:25.
The Entire Business World on a Single Page. Free to Use →